ProfileGDS5678 / 1423104_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 75% 75% 79% 80% 79% 73% 79% 84% 85% 81% 76% 81% 79% 76% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 14.9513175
GSM967853U87-EV human glioblastoma xenograft - Control 24.9929675
GSM967854U87-EV human glioblastoma xenograft - Control 35.4732679
GSM967855U87-EV human glioblastoma xenograft - Control 45.7410480
GSM967856U87-EV human glioblastoma xenograft - Control 55.624779
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.6666173
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 25.4169579
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 36.1362284
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 46.3349585
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 15.8787581
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 25.1377376
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 35.8713981
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 45.4470879
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 55.0661976